请选择 进入手机版 | 继续访问电脑版

搜索

Training Session on WHO and China Guide for Hepatitis C held in Xining, Qinghai

2019-10-13 15:44/ 发布者: Jiao/ 查看: 974/ 评论: 0



Sponsored by China Liver Health and co-organized by the Fourth People's Hospital of Qinghai Province and the infectious disease branch and liver disease Branch of Qinghai Provincial Medical Association, the training session on WHO and national guidelines for hepatitis C prevention and control was held in Xining, Qinghai province on Oct 13, 2019. More than 110 first-line healthcare workers from departments of infectious disease, liver disease, digestive diseases and laboratory medicine in over 11 hospitals in Xining and surrounding cities and counties participated in the training.

 

Guests on the rostrum


Academician Zhuang Hui (honorary chairman of China Liver Health), Dr. Chen Zhongdan from WHO Representative Office in China, secretary Liu Zhongfu from the National Center for AIDS/STD Control and Prevention under China CDC, director Li Mingyang from China Liver Health, Prof. Huang Yuan from Beijing Tsinghua Chang Gung Hospital and other experts attended the training session. She Qilu, deputy director and a member of the party group of Health Commission of Qinghai Province, attended the meeting and delivered a speech. Vice president Zhuo Ma of the Fourth People's Hospital of Qinghai Province delivered a speech on behalf of co-organizers. Lu Qinghua, director of the department of hepatology of the Fourth People's Hospital of Qinghai Province, presided over the meeting.


At the training session


This event is one of the series of activities of the China Hepatitis C Elimination Alliance Public Welfare Project. With academician Zhuang Hui, a foremost authority on hepatology, serving as the general counsel and based on WHO and national guidelines for hepatitis C prevention and control, the project aims to implement the National Viral Hepatitis Prevention and Control Plan (2017-2020) and promote the integration of national hepatitis C screening and management standard with international standards so as to improve the cure rate of hepatitis C and strengthen management of adverse reactions.

 

Deputy director She Qilu from the Health Commission of Qinghai Province delivered a speech.

 

Deputy president Zhuo Ma from the Fourth People's Hospital of Qinghai Province delivered a speech.

 

Director Lu Qinghua from the Fourth People's Hospital of Qinghai Province

presided over the meeting.

 
Deputy director She Qilu from the Health Commission of Qinghai Province expressed gratitude to liver disease experts for their efforts in eliminating hepatitis. He pointed out that eliminating hepatitis C was one of the major tasks in implementing Healthy China 2030 initiative. By actively integrating social resources to jointly promote hepatitis C screening, detection, prevention and treatment, China Hepatitis C Elimination Alliance Public Welfare Project would be an effective attempt for infectious disease prevention and control.

Academician Zhuang Hui (honorary chairman of China Liver Health), Dr. Chen Zhongdan from WHO Representative Office in China, and secretary Liu Zhongfu from the National Center for AIDS/STD Control and Prevention under China CDC conferred the plaque to deputy president Zhuo Ma from the Fourth People's Hospital of Qinghai Province.

 

 Group photo at the awarding ceremony

 
Academician Zhuang Hui (honorary chairman of China Liver Health) interpreted the epidemic situation and disease burden of hepatitis in Chinese mainland . There are about 10 million people infected with hepatitis C virus (HCV) domestically. According to the Global Health Sector Strategy (GHSS) on Viral Hepatitis adopted by the World Health Assembly, China should achieve the goal of 90% of HCV infections being diagnosed and 80% of confirmed cases being treated by 2030. In terms of this goal, healthcare workers in China still have a long way to go.
 
 

Academician Zhuang Hui interpreted the epidemic situation

and disease burden of hepatitis in Chinese mainland.

 
    Secretary Liu Zhongfu from the National Center for AIDS/STD Control and Prevention under China CDC and Dr. Chen Zhongdan from WHO representative office in China interpreted the disease burden, prevention and control status of hepatitis C and current challenges in China and worldwide respectively.

 
 

Secretary Liu Zhongfu introduced the epidemic status and prevention

and control progress of hepatitis in China. 

 

Dr. Chen Zhongdan introduced the global strategy

for viral hepatitis prevention and control.

 

Prof. Huang Yuan from Center of the Hepatobiliary and Pancreatic Diseases of Beijing Tsinghua Chang Gung Hospital and director Zu Hongmei from the department of hepatology of the Fourth People's Hospital of Qinghai Province interpreted the WHO and national guidelines for hepatitis C prevention and control, and discussed the epidemic status of hepatitis C, antiviral treatment for special hepatitis C patients and how to easily and effectively clear HCV.

 

Prof. Huang Yuan from Beijing Tsinghua Chang Gung Hospital

 

 Director Zu Hongmei from the Fourth People's Hospital of Qinghai Province

 

Director Li Mingyang introduced the China Hepatitis C Elimination Alliance Public Welfare Project.

 

Director Li Mingyang from China Liver Health said that, under the guidance of Health Commission of Qinghai Province, the China Hepatitis C Elimination Alliance Public Welfare Project would carry out in-depth cooperation with local hospitals and professional associations, provide supports for primary health care institutions to carry out health education for hepatitis C prevention and control in communities, provide help in the detection and diagnosis of high-risk groups so as to contribute to hepatitis C elimination in Xining.

 

[Background Information]

Viral hepatitis C (referred to as hepatitis C) is a blood-borne and sexually transmitted disease which can progress to severe diseases such as liver fibrosis, cirrhosis, and liver cancer, causing serious disease burden to the society and families. Hepatitis C can be completely cured with oral direct-acting antivirals (DAAs). In China, there are 10 million people infected with HCV. However, due to the insidious onset, insufficient attention from patients, high costs of drugs and other reasons, most of them have not been detected and effectively treated.

The China Hepatitis C Elimination Alliance Public Welfare Project is sponsored by China Liver Health and co-organized by the Research Center of Infectious Diseases under Peking University, Chinese Foundation for Hepatitis Prevention and Control,Peking University Hepatology Institute, the hepatology branch and infectious disease branch of Chinese Medical Association, Hepatology Institute of Jilin Province, Virtual Community of Hepatitis C, and Health Times of People’s Daily. It aims to promote the diagnosis and treatment of hepatitis C, implement the National Viral Hepatitis Prevention and Control Plan (2017-2020), and cooperate with the World Health Organization to reach the strategic goal of eliminating viral hepatitis as a major public health threat by 2030.



相关分类

返回顶部